Skip to content

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Third-generation EGFR-TKI plus pemetrexed-platinum chemotherapy versus TKI monotherapy as first-line treatment for EGFR-mutant lung adenocarcinoma with brain parenchymal metastases

Objective To evaluate the efficacy and safety of first-line third-generation EGFR-tyrosine kinase inhibitor (EGFR-TKI) combined with pemetrexed-platinum chemotherapy in patients with EGFR-mutant advanced lung adenocarcinoma and brain parenchymal metastases. Methods A bicenter retrospective cohort study was conducted. A...

Jian-Xi Zhou, Ying-Hao Wang, Kang Wen et al. · 0 citations
Open access Sep 2026

Ivonescimab Plus Chemotherapy versus Bevacizumab Plus Chemotherapy in EGFR-Mutant Lung Adenocarcinoma After EGFR-TKI Failure: A Two-Center Retrospective Real-World Propensity Score-Matched Study

Objective To evaluate the efficacy and safety of ivonescimab plus chemotherapy versus bevacizumab plus chemotherapy in advanced EGFR-mutant lung adenocarcinoma after EGFR-TKI failure, and provide the first real-world head-to-head comparative evidence. Methods This two-center retrospective propensity score-matched (PSM)...

Jian-Xi Zhou, Ying-Hao Wang, Kang Wen et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.